ストックスクリーナーアプリを入手
0.7005
0.01%
0.000100
前日終値:
$0.7004
開ける：
$0.7019
24時間の取引高:
8,170
Relative Volume:
0.03
時価総額：
$2.78M
収益：
-
当期純損益:
$-9.34M
株価収益率:
-0.0981
EPS:
-7.14
ネットキャッシュフロー:
$-6.69M
1週間 パフォーマンス:
+9.15%
1か月 パフォーマンス:
-27.08%
6か月 パフォーマンス:
-51.01%
1年 パフォーマンス:
-79.70%
1日の値動き範囲:
$0.70
$0.71
1週間の範囲:
$0.6639
$0.74
52週間の値動き範囲:
$0.611
$6.65
Painreform Ltd Stock (PRFX) Company Profile
PRFX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRFX
Painreform Ltd
|
0.7089 | 2.74M | 0 | -9.34M | -6.69M | -7.14 |
|
ZTS
Zoetis Inc
|
127.81 | 57.00B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.95 | 49.88B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.07 | 45.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.41 | 36.84B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
506.44 | 21.64B | 3.08B | 1.24B | 1.07B | 25.61 |
Painreform Ltd (PRFX) 最新ニュース
Can PainReform Ltd. stock deliver sustainable ROE2026 world cup usa national team third place match playmakers possession football match prediction preview - Улправда
PainReform Shareholders Approve All Proposals at Adjourned 2026 Annual Meeting - TipRanks
PainReform Ltd's Deepsolar Launches Smart TDD, A Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market - marketscreener.com
PainReform (PRFX) Introduces Advanced Solar Audit Service with S - GuruFocus
PainReform’s DeepSolar Unveils Smart TDD to Speed and Sharpen Solar Asset Due Diligence - TipRanks
PainReform Ltd. Launches Smart TDD: Advanced Solar Technical Due Diligence Service to Enhance Asset Performance and Risk Assessment - Quiver Quantitative
PainReform’s DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market - Yahoo Finance
PainReform Ltd. (PRFX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PainReform Adjourns Annual Shareholder Meeting Due to Lack of Quorum - TipRanks
AI drones join $600B push to keep UAE and Middle East solar farms efficient - Stock Titan
Is PainReform Ltd stock attractive after correctionWeekly Stock Summary & Weekly Watchlist for Hot Stocks - moha.gov.vn
Why PainReform Ltd. stock remains on buy listsTrade Risk Summary & Daily Oversold Stock Bounce Ideas - Улправда
Can PainReform Ltd. stock surprise with earnings upside2025 Price Action Summary & Growth Focused Entry Reports - Улправда
Published on: 2025-12-19 20:32:49 - Улправда
Published on: 2025-12-19 20:05:02 - Улправда
Is PainReform Ltd. stock overvalued by current metricsWeekly Trend Recap & Daily Volume Surge Signals - Улправда
What hedge fund activity signals for PainReform Ltd. stockPrice Action & Long-Term Investment Growth Plans - DonanımHaber
How risky is PainReform Ltd. stock nowWall Street Watch & Long-Term Safe Investment Ideas - DonanımHaber
Is PainReform Ltd. stock attractive for income investorsWeekly Stock Summary & AI Powered Market Trend Analysis - Улправда
What drives PainReform Ltd stock priceTop Performing Stocks & Download Our Free Trading Blueprint - earlytimes.in
PainReform completed R&D assessment of LayerBio’s drug-delivery platform - MSN
Published on: 2025-12-13 11:33:01 - moha.gov.vn
Trend Recap: How PainReform Ltd stock performs after earningsQuarterly Investment Review & Proven Capital Preservation Methods - moha.gov.vn
PainReform’s LayerBio Platform Advances with Multi-Drug Capability - TipRanks
PainReform Ltd. Completes R&D Assessment of LayerBio's Sustained-Release Ocular Drug-Delivery Platform - Quiver Quantitative
PainReform (Nasdaq: PRFX) validates LayerBio drop-less ocular platform for multi-drug cataract care - Stock Titan
PainReform commences development plan for OcuRing-K Phase II trial - MSN
Is PainReform Ltd (PRFX) positioned for future growth? - Setenews
Will PainReform Ltd. stock pay special dividendsPortfolio Profit Report & Growth Oriented Trade Recommendations - Newser
Will PainReform Ltd. stock maintain dividend yieldMarket Volume Summary & Stock Portfolio Risk Management - Newser
PainReform Ltd. Commences Development for OcuRing??-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy - marketscreener.com
PainReform begins development plan for drop-less cataract surgery therapy By Investing.com - Investing.com
PainReform (PRFX) Advances OcuRing-K Development for Improved Ca - GuruFocus
PainReform Initiates Phase II Development for OcuRing™-K - TipRanks
Painreform commences development for Ocuring-K phase II trial - marketscreener.com
PainReform begins development plan for drop-less cataract surgery therapy - Investing.com
PainReform Commences Development for OcuRing™-K Phase II - GlobeNewswire
PainReform (Nasdaq: PRFX) moves OcuRing-K into Phase II plan in $9B cataract market - Stock Titan
PainReform Ltd. (PRFX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
PainReform’s DeepSolar Advances with NVIDIA Connect and Pilot Projects - MSN
PainReform schedules annual shareholder meeting for December 30 in Tel Aviv - Investing.com
PainReform Ltd. Announces December 2025 Shareholders Meeting with Key Proposals - TipRanks
Longview Tea Company Limited Stock Analysis Technical Signals for 2025High Beta Stocks & Small Investment Capital Tips - earlytimes.in
Painreform Ltd (PRFX) 財務データ
収益
当期純利益
現金流量
EPS
1.35%
2.56%
大文字化:
|
ボリューム (24 時間):